Jennison Associates
CGON icon

Jennison Associates’s CG Oncology CGON Stock Holding History

Jennison Associates’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.5M Sell
317,235
-158,901
-33% -$10.4M 0.01% 324
2026
Q1 		$32.2M Buy
476,136
+193,630
+69% +$11M 0.02% 277
2025
Q4 		$11.7M Buy
+282,506
New +$11.7M 0.01% 382

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates's CGON Position: Q2 2026 in Review

Jennison Associates reduced its CG Oncology (CGON) stake by 33% in Q2 2026, selling an estimated $10.4M and leaving 317,235 shares worth $22.5M. The position accounts for 0.01% of the portfolio, ranked #324.

Jennison Associates first reported a position in CGON in Q4 2025 and has held it in 3 quarters since. The position peaked at $32.2M in Q1 2026. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Jennison Associates held 317,235 shares of CG Oncology worth $22.5M as of Q2 2026.
  • Jennison Associates sold 158,901 CG Oncology shares in Q2 2026, an estimated $10.4M.
  • CG Oncology made up 0.01% of Jennison Associates's portfolio in Q2 2026, its #324 holding.
  • Jennison Associates first reported a position in CG Oncology in Q4 2025 and has held it in 3 quarters since.
  • Jennison Associates's CG Oncology position peaked at $32.2M in Q1 2026.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Jennison Associates's 13F filing for Q2 2026, filed 3 Aug 2026.